Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELZ Creative Medical Technology	$3.19 +0.9%	$2.83	$1.69 ▼ $6.90	$8.15M	2.04	170,314 shs	43,486 shs
EVOK Evoke Pharma	$5.53 -12.8%	$4.31	$1.94 ▼ $12.32	$9.88M	-0.04	473,034 shs	157,812 shs
KPRX Kiora Pharmaceuticals	$2.73 +4.2%	$2.85	$2.25 ▼ $4.18	$9M	-0.64	87,042 shs	27,058 shs
UPC Universe Pharmaceuticals	$3.50 +2.0%	$3.72	$2.51 ▼ $2,064.00	$1.97M	1.43	266,154 shs	17,325 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELZ Creative Medical Technology	+0.95%	+2.24%	+15.16%	+57.92%	-3.92%
EVOK Evoke Pharma	-12.78%	+8.01%	+22.35%	+51.26%	+13.79%
KPRX Kiora Pharmaceuticals	+4.20%	-6.83%	-12.22%	-10.78%	-33.41%
UPC Universe Pharmaceuticals	+0.57%	-1.82%	-8.62%	-25.05%	-99.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELZ Creative Medical Technology	1.5775 of 5 stars	0.0	5.0	0.0	0.0	3.9	0.0	0.6
EVOK Evoke Pharma	0.4305 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.0
KPRX Kiora Pharmaceuticals	2.801 of 5 stars	3.3	5.0	0.0	0.0	1.1	1.7	0.6
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELZ Creative Medical Technology	2.00	Hold	N/A	N/A
EVOK Evoke Pharma	0.00	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	2.50	Moderate Buy	$10.00	266.30% Upside
UPC Universe Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest UPC, EVOK, KPRX, and CELZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
8/13/2025	KPRX Kiora Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2025	CELZ Creative Medical Technology	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELZ Creative Medical Technology	$10K	823.02	N/A	N/A	$2.65 per share	1.20
EVOK Evoke Pharma	$10.25M	0.84	N/A	N/A	$2.81 per share	1.97
KPRX Kiora Pharmaceuticals	$16.02M	0.58	$1.29 per share	2.11	$6.44 per share	0.42
UPC Universe Pharmaceuticals	$19.29M	0.10	N/A	N/A	$163.50 per share	0.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELZ Creative Medical Technology	-$5.49M	-$3.18	N/A	N/A	N/A	N/A	-82.99%	-79.49%	N/A
EVOK Evoke Pharma	-$5.35M	-$2.56	N/A	∞	N/A	-42.07%	-99.48%	-33.58%	11/5/2025 (Estimated)
KPRX Kiora Pharmaceuticals	$3.60M	-$2.91	N/A	N/A	N/A	N/A	-47.17%	-34.00%	N/A
UPC Universe Pharmaceuticals	-$6.16M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest UPC, EVOK, KPRX, and CELZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EVOK Evoke Pharma	-$0.30	-$0.62	-$0.32	-$0.62	$3.80 million	$3.75 million
8/8/2025	Q2 2025	CELZ Creative Medical Technology	-$0.63	-$0.48	+$0.15	-$0.48	N/A	N/A
8/8/2025	Q2 2025	KPRX Kiora Pharmaceuticals	-$0.58	-$0.54	+$0.04	-$0.54	$0.75 million	$0.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELZ Creative Medical Technology	N/A	N/A	N/A	N/A	N/A
EVOK Evoke Pharma	N/A	N/A	N/A	N/A	N/A
KPRX Kiora Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
UPC Universe Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELZ Creative Medical Technology	N/A	23.86	23.86
EVOK Evoke Pharma	N/A	1.37	1.50
KPRX Kiora Pharmaceuticals	N/A	7.76	7.76
UPC Universe Pharmaceuticals	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELZ Creative Medical Technology	1.42%
EVOK Evoke Pharma	N/A
KPRX Kiora Pharmaceuticals	76.97%
UPC Universe Pharmaceuticals	0.18%

Insider Ownership

Company	Insider Ownership
CELZ Creative Medical Technology	2.80%
EVOK Evoke Pharma	2.29%
KPRX Kiora Pharmaceuticals	0.05%
UPC Universe Pharmaceuticals	57.38%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELZ Creative Medical Technology	5	2.58 million	2.51 million	Not Optionable
EVOK Evoke Pharma	4	1.56 million	1.52 million	Not Optionable
KPRX Kiora Pharmaceuticals	10	3.43 million	3.43 million	Not Optionable
UPC Universe Pharmaceuticals	220	563,000	731,000	Not Optionable

UPC, EVOK, KPRX, and CELZ Headlines

Recent News About These Companies

Universe Pharmaceuticals Inc. (UPC) Stock Price Today - WSJ

August 7, 2025 | wsj.com

Pharma Playbook: What Practitioners Can Learn from Early UPC Litigation

May 14, 2025 | ipwatchdog.comI

Universe Pharmaceuticals Reports Full Year 2024 Earnings

May 3, 2025 | finance.yahoo.com

Universe Pharmaceuticals INC Announces Share Consolidation Effective March 24, 2025

March 20, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | gurufocus.com

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | investing.com

Universe Pharmaceuticals INC Announces Share Consolidation

March 20, 2025 | globenewswire.com

Universe Pharmaceuticals Approves Share Consolidation at Extraordinary Meeting

March 11, 2025 | tipranks.com

Universe Pharmaceuticals INC Faces Potential Delisting from Nasdaq Due to Delinquent Annual Report Filing

February 25, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

February 25, 2025 | globenewswire.com

Universe Pharmaceuticals proposes revised share consolidation

February 11, 2025 | msn.com

Universe Pharmaceuticals (NASDAQ:UPC) Stock, Short Interest Report

February 10, 2025 | benzinga.com

Universe Pharmaceuticals INC.: Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

February 6, 2025 | finanznachrichten.de

UPC’s Unexpected Plunge: What’s Next?

February 5, 2025 | bovnews.comB

Universe Pharmaceuticals gets Nasdaq delisting notice

February 4, 2025 | markets.businessinsider.com

Universe Pharmaceuticals INC Faces Nasdaq Delisting Due to Low Share Price

February 3, 2025 | quiverquant.comQ

Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

February 3, 2025 | globenewswire.com

Universe Pharmaceuticals announces shareholder meeting

January 30, 2025 | msn.com

Universe Pharmaceuticals stock hits 52-week low at $0.48 amid steep decline

January 29, 2025 | msn.com

Universe Pharmaceuticals Inc (UPC) Stock: A Deeper Look at Its True Potential

December 29, 2024 | bovnews.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

UPC, EVOK, KPRX, and CELZ Company Descriptions

Creative Medical Technology NASDAQ:CELZ

$3.19 +0.03 (+0.95%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.15 -0.04 (-1.25%)

As of 08/22/2025 07:42 PM Eastern

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Evoke Pharma NASDAQ:EVOK

$5.53 -0.81 (-12.78%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.89 -0.64 (-11.57%)

As of 08/22/2025 07:59 PM Eastern

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Kiora Pharmaceuticals NASDAQ:KPRX

$2.73 +0.11 (+4.20%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.68 -0.05 (-1.83%)

As of 08/22/2025 07:47 PM Eastern

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Universe Pharmaceuticals NYSE:UPC

$3.50 +0.07 (+2.04%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$3.58 +0.08 (+2.40%)

As of 08/22/2025 04:31 PM Eastern

Universe Pharmaceuticals INC, through its subsidiaries, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was founded in 1998 and is based in Ji'An, China. Universe Pharmaceuticals INC operates as a subsidiary of Sununion Holding Group Limited.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time